32 results about "RUNX1" patented technology

The invention discloses a combined genome for evaluating prognosis of clear cell renal cell carcinoma (ccRCC) and application of the combined genome, relates to the technical field of medical biological detection, and provides novel application of the combined genome of ADAMTS9, C1S, DPYSL3, H2AFX, MINA, PLOD2, RUNX1, SLC19A1, TPX2 and TRIB3, particularly application in preparation of a ccRCC prognosis evaluation reagent or kit. The genome is derived from a molecular marker significantly correlated with a ccRCC metastasis way, and the discovery of the genome model provides a new strategy for predicting the ccRCC recurrent risk and the long-term survival condition of a patient after operation, plays important roles in judging the prognosis of the ccRCC patient, can evaluate the risk level of tumor progression or death of the patient after ccRCC operation, contributes to guiding a clinician to perform an individualized precise therapeutic strategy, can increase the postoperative survivalrate of the patient, and has important guide significance postoperative follow-up monitoring and sequential therapy management of the ccRCC patient.

The invention belongs to the technical field of RUNX1 gene splitting and copy number increase detection and provides a RUNX1 gene splitting and copy number increase detection kit and a preparation method thereof. A probe for detecting gene splitting is designed according to the characteristic of gene splitting. The preparation method is characterized by selecting RP11-177L11BAC and RP11-77I17BAC clones and respectively marking RP11-177L11BAC and RP11-77I17BAC with green and red to serve as probe sequences, carrying out FISH (fluorescence in situ hybridization) on the sequences and a cell to be detected after purifying, precipitating and dissolving the sequences, and carrying out fluorescent microscopic observation on cell signals, wherein normal somatic cells have two yellow signals; once genes are split, one red signal, one green signal and one yellow signal appear, and the corresponding quantity of yellow signals appear when the copy number increases. By adopting the kit and the preparation method, the method for accurately detecting gene splitting is created, the defects of the existing gene splitting detection means are overcome, the RUNX1 gene splitting and copy number increase incidents are rapidly and accurately detected and identified, and partner genes fused with an RUNX1 gene are determined in combination with subsequent RACE (rapid amplification of cDNA ends) detection.

A kit for detecting esophagus cancer related risky genes is disclosed. The kit includes: specific primer pairs, specific fluorescence probe pairs, common components for fluorogenic quantitative PCR detection; and the like, wherein the specific primer pairs and the specific fluorescence probe pairs are used for simultaneously detecting a number rs2274223 SNP site on a PLCE1 gene, a number rs13042395 SNP site on a C20orf54 gene, a number rs2074356 SNP site on a C12orf51 gene, a number rs2014300 SNP site on an RUNX1 gene, a number rs11066015 SNP site on an ACAD10 gene and a number rs10052657 SNP site on a PDE4D gene. The kit evaluates the risk of esophagus cancer for a person through simultaneously detecting single nucleotide polymorphic site genotypes of the PLCE1, the C20orf54, the C12orf51, the RUNX1, the ACAD10 and the PDE4D which are closely related with the esophagus cancer.

The invention discloses a method for screening a miR-181b target gene. The method comprises the following steps: taking a goat ovarian tissue cDNA (complementary Deoxyribonucleic Acid) as a template and carrying out amplification in the presence of Taq DNA polymerase, a buffering environment, Mg<2+> and dNTPs by utilizing a primer RUNX1 under the condition of PCR (Polymerase Chain Reaction), so asto obtain a determined PCR product which is a sequence of a 3' UTR region of an RUNX1 gene; then constructing a dual-luciferase reporting system and detecting the activity of luciferase; primarily identifying the miR-181b target gene; detecting the influences, caused by the fact that miR-181b is detected by adopting an RT-qPCR method, on the level of an RUNX1 gene on mRNA (massager Ribonucleic Acid); detecting the influences, caused by the fact that the miR-181b is detected by adopting a Western blot method, on a protein level of the RUNX1 gene. A combination site with the miR-181b exists inthe RUNX1 3' UTR region; a modern molecular biotechnology is used for verifying a targeting regulation relation of the miR-181b and the target gene RUNX1 and the miR-181b can be used for inhibiting the expression of the RUNX1 gene in the mRNA and protein levels; furthermore, the method confirms that the RUNX1 is a target gent of the miR-181b. The method lays a foundation for further researching influences, caused by the miR-181b, on ovarian development and lambing performance of dairy goats.

The invention provides a kit for combined detection of acute myeloid leukemia. The kit comprises a special linker for DNA library construction, a specific composite primer for detecting gene rearrangement and gene whole exon mutation, and a composite primer for library amplification. The special linker is 8 dimers formed by a linker primer 1 and eight different i5-terminal primers respectively; the types of the gene rearrangement and the gene whole exon mutation are CBFB rearrangement, RUNX1 rearrangement, MLL rearrangement, RARA rearrangement, MECOM rearrangement and TP53 gene whole exon mutation; and the composite primer for library amplification has different i7 terminals. The kit provided by the invention can be used for detecting a plurality of common molecular genetic variations of acute myeloid leukemia at one time, and is simple to operate, short in time and high in detection efficiency.

The present invention relates to a kind of mixed gene that is used for detecting fusion gene, and its gene sequence is as shown in SEQ ID NO:1, comprises the BCR-ABL fusion gene of SEQ ID NO:2, the AML-ETO fusion gene of SEQ ID NO:3 , the PML-RARA fusion gene of SEQ ID NO:4 and the ABL internal reference gene of SEQ ID NO:5; also relate to the standard plasmid that contains mixed gene, comprise the PUC57 plasmid of SEQ ID NO:6; Also relate to a kind of standard plasmid that contains The kit; also relates to a preparation method of a standard plasmid. Its advantage is, can be used for in the leukemia-associated fusion gene in quantitative detection people's bone marrow or peripheral blood sample BCR-ABL, RUNX1-RUNX1T1 (AML-ETO) and PML-RARA fusion gene double standard curve establishment; Effectively improve Improve detection efficiency and accuracy, reduce human error, and avoid multi-plasmid contamination; the minimum detection copy number of standard plasmids is 1*10 0 pcs / ml; easy to operate, not easy to pollute, large detection range, can effectively reduce detection cost.

The invention belongs to the technical field of RUNX1 gene splitting and copy number increase detection and provides a RUNX1 gene splitting and copy number increase detection kit and a preparation method thereof. A probe for detecting gene splitting is designed according to the characteristic of gene splitting. The preparation method is characterized by selecting RP11-177L11BAC and RP11-77I17BAC clones and respectively marking RP11-177L11BAC and RP11-77I17BAC with green and red to serve as probe sequences, carrying out FISH (fluorescence in situ hybridization) on the sequences and a cell to be detected after purifying, precipitating and dissolving the sequences, and carrying out fluorescent microscopic observation on cell signals, wherein normal somatic cells have two yellow signals; once genes are split, one red signal, one green signal and one yellow signal appear, and the corresponding quantity of yellow signals appear when the copy number increases. By adopting the kit and the preparation method, the method for accurately detecting gene splitting is created, the defects of the existing gene splitting detection means are overcome, the RUNX1 gene splitting and copy number increase incidents are rapidly and accurately detected and identified, and partner genes fused with an RUNX1 gene are determined in combination with subsequent RACE (rapid amplification of cDNA ends) detection.

The invention discloses a kit for predicting the prognosis risk of lung squamous cell carcinoma and its application, and relates to the technical fields of genetic engineering and oncology. The kit can detect the sequence information of the target region, and the target region is selected from the regions in Table 1 1-127, which are located in the specific regions of ARID1A, SLC43A2, ANKS1A, CHD2, RPTOR, OR7A5 and RUNX1 genes. By detecting the sequence information of the target regions, it can effectively and quickly predict the prognosis risk of lung squamous cell carcinoma patients. These targets Compared with other clinical markers, regional mutations have higher specificity, and the detection is convenient and quick.

The invention discloses a method and primers for detecting a fifth exon mutation site of a RUNX1 gene. The method and the primers comprise a forward primer, a reverse primer and a pair of sequencing primers for amplifying the fifth exon mutation site of the RUNX1 gene. The method combines a Touch-down PCR amplification and a Sanger sequencing method, can rapidly detect mutation conditions of the fifth exon mutation site of the RUNX1 gene in an acute myeloid leukemia patient body.

The invention provides a kit for joint detection of acute myeloid leukemia, which includes special adapters for DNA library construction and specific compound primers for detecting gene rearrangement and gene whole exon mutation and composite primers for library amplification. The special linker is 8 dimers composed of linker primer 1 and 8 different i5 end primers respectively; the types of gene rearrangement and gene whole exon mutation are CBFB rearrangement, RUNX1 rearrangement, MLL rearrangement, RARA rearrangement, MECOM rearrangement, whole exon mutation of TP53 gene; library amplification compound primers have different i7 ends. The kit provided by the invention can detect multiple common molecular genetic variations of acute myeloid leukemia at one time, and has simple operation, short time and high detection efficiency.

The invention provides a preparation method and application of human hematopoietic progenitor cells with B lineage differentiation potential. The preparation method comprises: introducing three transcription factors RUNX1, HOXA9 and LHX2 into a human pluripotent stem cell induction differentiation system simultaneously or separately The cells of the human pluripotent stem cell induced differentiation system include human pluripotent stem cells, mesoderm cells, hematopoietic endothelial cells or Any one or a combination of at least two of the hematopoietic progenitor cells; the method for inducing differentiation includes a method for inducing differentiation by monolayer culture based on co-culture of stromal cells or a method for inducing differentiation by three-dimensional culture of organoids. The preparation method has good induction and differentiation efficiency, and the prepared cells have good activity and high differentiation ability, and have important application value.

This invention relates to compounds that bind to wild-type CBFβ and inhibit CBFβ binding to RUNX proteins. The potent compounds of the invention inhibit this protein-protein interaction at low micromolar concentrations, using allosteric mechanism to achieve inhibition, displace wild-type CBFβ from RUNX1 in cells, change occupancy of RUNX1 on target genes, and alter gene expression of RUNX1 target genes. These inhibitors show clear biological effects consistent with on-target RUNX protein activity. Pharmaceutical compositions containing a compound of the invention and a pharmaceutically acceptable carrier represent a separate embodiment of the invention. Another embodiment of the invention are methods of treating a RUNX-signaling-dependent cancer that expresses wild-type CBFβ in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the invention. In one embodiment, the cancer is selected from the group consisting of a RUNX-signaling-dependent leukemia that expresses wild-type CBFβ, lung cancer, bladder cancer, ovarian cancer, uterine cancer, endometrial cancer, breast cancer, liver cancer, pancreatic cancer, stomach cancer, cervical cancer, lymphoma, leukemia, acute myeloid leukemia, acute lymphocytic leukemia, salivary gland cancer, bone cancer, brain cancer, colon cancer, rectal cancer, colorectal cancer, kidney cancer, skin cancer, melanoma, squamous cell carcinoma of the tongue, pleomorphic adenoma, hepatocellular carcinoma, pancreatic cancer, squamous cell carcinoma, and / or adenocarcinoma. In another embodiment, the compounds of the invention can be used to treat a leukemia, lung cancer, ovarian cancer, and / or breast cancer.

The invention discloses a primer pair RUNXF / RUNXR for detecting a gene polymorphism site of RUNX1 rs2268277 by using a PCR (Polymerase Chain Reaction) method, wherein the sequences of the primer pair are as shown in SEQ ID NO.1 and SEQ ID NO.2 respectively. The invention further discloses the application of the primer pair RUNXF / RUNXR in detecting the gene polymorphism site of a biological sample IMPDH1 rs4731447, and a detection kit which is prepared from the primer pair and used for detecting the gene polymorphism site of the RUNX1 rs2268277. By adopting the primer pair and the PCR method of the primer pair disclosed by the invention, the gene type of the gene polymorphism site of the RUNX1 rs2268277 can be confirmed according to amplification electrophoresis results, the treatment effect and the side effect of a purinethol medicine can be predicted, the effectiveness and the security of the purinethol medicine administrated to a patient can be predicted on the basis of gene type analysis, clinical medicine administration can be instructed, and individual treatment on patients can be achieved.